Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.

Authors :: Koshino A
Oshima M
Arnott C
Fletcher RA
Bakris GL
Jardine M
Mahaffey KW
Perkovic V
Pollock C
Heerspink HJL
Neuen BL
Source :: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 May; Vol. 25 (5), pp. 1413-1418. Date of Electronic Publication: 2023 Feb 06.
Publication Year :: 2023

Subjects :: Humans
Canagliflozin therapeutic use
Fibrosis
Cardiovascular Diseases
Diabetes Mellitus, Type 2 complications
Diabetes Mellitus, Type 2 drug therapy
Fatty Liver complications
Fatty Liver drug therapy
Renal Insufficiency, Chronic complications
Renal Insufficiency, Chronic drug therapy

Full Text Access

Tools